WordNet

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/11/14 22:31:32」(JST)

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 前立腺癌における化学的予防策 chemoprevention strategies in prostate cancer
2. 前立腺肥大症の内科的治療 medical treatment of benign prostatic hyperplasia
3. 男性における男性型脱毛症の治療 treatment of androgenetic alopecia in men
4. 男性における下部尿路症状 lower urinary tract symptoms in men
5. 女性型脱毛症（女性のアンドロゲン性脱毛症）：治療および予後 female pattern hair loss androgenetic alopecia in women treatment and prognosis

DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence.

Horning AM1, Awe JA2,3,4, Wang CM1, Liu J1, Lai Z5,6, Wang VY1, Jadhav RR1, Louie AD1, Lin CL1, Kroczak T7, Chen Y5,6,8, Jin VX1,8, Abboud-Werner SL9, Leach RJ5,10,11, Hernandez J11, Thompson IM5,11, Saranchuk J7, Drachenberg D7, Chen CL1, Mai S2, Huang TH1,5.
The Prostate.Prostate.2015 Nov;75(15):1790-801. doi: 10.1002/pros.23052. Epub 2015 Sep 1.
BACKGROUND: Altered DNA methylation in CpG islands of gene promoters has been implicated in prostate cancer (PCa) progression and can be used to predict disease outcome. In this study, we determine whether methylation changes of androgen biosynthesis pathway (ABP)-related genes in patients' plasma c
PMID 26332453

Age and Obesity Promote Methylation and Suppression of 5α-Reductase 2: Implications for Personalized Therapy of Benign Prostatic Hyperplasia.

Bechis SK1, Otsetov AG1, Ge R1, Wang Z1, Vangel MG2, Wu CL3, Tabatabaei S1, Olumi AF4.
The Journal of urology.J Urol.2015 Oct;194(4):1031-7. doi: 10.1016/j.juro.2015.04.079. Epub 2015 Apr 25.
PURPOSE: In men with symptomatic benign prostatic hyperplasia 5α-reductase inhibitors are a main modality of treatment. More than 30% of men do not respond to the therapeutic effects of 5α-reductase inhibitors. We have found that a third of adult prostate samples do not express 5α-reductase type
PMID 25916673

SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy.

Shiota M1, Fujimoto N2, Yokomizo A3, Takeuchi A1, Itsumi M1, Inokuchi J1, Tatsugami K1, Uchiumi T4, Naito S1.
European journal of cancer (Oxford, England : 1990).Eur J Cancer.2015 Sep;51(14):1962-9. doi: 10.1016/j.ejca.2015.06.122. Epub 2015 Jul 11.
AIM: De novo androgen synthesis is thought to be involved in the progression to castration-resistant prostate cancer (CRPC) during androgen-deprivation therapy (ADT). During androgen synthesis, 5α-reductase encoded by SRD5A catalyses testosterone into more active dihydrotestosterone and may be invo
PMID 26169017

cholestenone 5-alpha-reductase
Identifiers
EC number	1.3.1.22
CAS number	37255-34-8
Databases
IntEnz	IntEnz view
BRENDA	BRENDA entry
ExPASy	NiceZyme view
KEGG	KEGG entry
MetaCyc	metabolic pathway
PRIAM	profile
PDB structures	RCSB PDB PDBe PDBsum
Gene Ontology	AmiGO / EGO
Search
PMC	articles
PubMed	articles
NCBI	proteins